Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer
Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
Erika P. Hamilton, MD, director of the breast and gynecologic research program at Sarah Cannon Research Institute, discusses the results from a phase II study of abemaciclib (Verzenio) plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
The progression-free survival (PFS) range was 6.5 months to 9.1 months in this study and was not statistically significant across arms. Hamilton says the single-agent abemaciclib had equal activity in regard to PFS. Hamilton also noted the arm receiving 200 mg of abemaciclib had a response rate of 29% compared to 19% in the previous MONARCH trial.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
